Evidence-based Migraine Treatments Worth Trying Now
- 01. What works now
- 02. Non-drug and device-based care
- 03. Practical effectiveness - numbers clinicians use
- 04. Guideline and historical context
- 05. How clinicians choose - algorithm
- 06. Risks, safety, and misuse
- 07. High-value combinations
- 08. Cost, access, and equity
- 09. Key practical tips for patients
- 10. Representative clinical quote
- 11. Quick reference checklist for clinicians
Short answer: The best evidence-based migraine treatments combine prompt acute therapies (NSAIDs, triptans, gepants, antiemetics), individualized preventive medications (CGRP monoclonal antibodies, beta-blockers, antiepileptics, onabotulinumtoxinA for chronic migraine) and structured nonpharmacologic care (trigger management, CBT/biofeedback, sleep and lifestyle optimization), with choice guided by attack frequency, severity, comorbidity, and patient preference. Clinical guidelines published in 2025-2026 summarize these recommendations and show that combining pharmacologic and behavioural approaches yields the greatest reduction in monthly migraine days for most patients.
What works now
Acute treatments that reliably abort attacks include high-dose NSAIDs and triptans when taken early, with newer oral gepants and the 5-HT1F agonist lasmiditan as alternatives for people with vascular risk factors; antiemetics improve absorption and comfort when nausea is present. Acute treatments.
Preventive strategies that show consistent trial-level benefit include CGRP-targeted monoclonal antibodies (monthly or quarterly injections), oral options (propranolol, metoprolol, topiramate, amitriptyline) depending on comorbidities, and onabotulinumtoxinA specifically for chronic migraine (≥15 headache days/month). Preventive medications.
Non-drug and device-based care
Structured behavioural therapies-Cognitive Behavioural Therapy (CBT), biofeedback, and relaxation training-reduce attack frequency and disability when delivered over several sessions; regular aerobic exercise and sleep regularization produce measurable benefit. Behavioural therapies.
Neuromodulation devices (transcutaneous supraorbital nerve stimulation, noninvasive vagal stimulation) have moderate-quality evidence for either acute relief or prevention and are useful when medications are contraindicated or not tolerated. Neuromodulation devices.
Practical effectiveness - numbers clinicians use
Randomized controlled trials and guideline meta-analyses report realistic effect sizes clinicians use to counsel patients: approximately 50-60% of patients achieve ≥50% reduction in monthly migraine days with CGRP monoclonal antibodies at 12 weeks, while traditional oral preventives (beta-blockers, antiepileptics) show 30-50% achieving a similar response depending on drug and population. Response rates.
| Treatment class | % achieving ≥50% reduction | Primary indication |
|---|---|---|
| CGRP monoclonal antibodies | 50-60% | Frequent episodic, chronic prevention |
| OnabotulinumtoxinA | 40-55% | Chronic migraine (≥15 days/month) |
| Beta-blockers (propranolol) | 30-45% | Episodic prevention, comorbid hypertension |
| Topiramate | 35-50% | Episodic/chronic prevention |
| Acute triptans | 60-75% (pain relief at 2h) | Moderate-severe acute attacks |
| Gepants (ubrogepant/rimegepant) | 30-50% (pain freedom at 2h) | Acute; some also preventive |
Guideline and historical context
Modern migraine guidelines evolved from single-drug recommendations in the 1990s to multi-domain, evidence-graded pathways by the 2010s; the most influential updates in 2024-2025 incorporated CGRP antagonists and head-to-head trial data into formal recommendations. Guideline evolution.
The International Headache Society and national bodies published major updates in 2025 that standardized grading (GRADE) and emphasized individualized care, prompt acute treatment, limiting analgesic overuse, and earlier consideration of targeted biologics for eligible patients. 2025 guideline updates.
How clinicians choose - algorithm
Treatment selection is driven by attack frequency, severity, disability (MIDAS/HIT-6 scores), comorbidities, and patient preference; risk factors (pregnancy, cardiovascular disease) narrow safe options. Selection factors.
- Assess attack pattern and disability using validated instruments.
- Start targeted acute therapy (NSAID or triptan) and rescue antiemetic if needed.
- If attacks ≥4/mo or significant disability, initiate preventive therapy tailored to comorbidity.
- Reassess at 8-12 weeks; change or escalate if <50% reduction in monthly migraine days.
- Consider specialist referral for refractory or chronic migraine and nonresponse to two or more preventives.
Risks, safety, and misuse
Medication-overuse headache (MOH) is a key harm from excessive acute analgesic use; guideline advice is to limit simple analgesics to <2 days/week and to avoid frequent opioid or combination analgesic use. Medication-overuse.
CGRP-targeted therapies have favorable tolerability but require monitoring in certain vascular or pregnancy-related contexts; triptans are contraindicated in known ischemic heart disease. Safety considerations.
High-value combinations
Combining a preventive biologic with structured CBT and lifestyle routines produces greater decreases in monthly days and disability than any single intervention alone in pragmatic trials and real-world registries. Combined approach.
- Medication + CBT reduces attack frequency and improves coping skills.
- Medication + neuromodulation helps patients who cannot tolerate systemic drugs.
- Lifestyle (sleep, hydration, exercise) plus trigger management reduces recurrence and medication need.
Cost, access, and equity
CGRP monoclonal antibodies and device therapies are effective but cost and insurance coverage limit access in many health systems; tiered approaches (start with oral preventives, escalate when ineffective) remain common policy. Access issues.
Health systems increasingly use step pathways and prior authorization criteria (history of failed preventives) to manage budget impact while offering targeted therapy to the highest-need patients. Step pathways.
Key practical tips for patients
Take acute medication at the earliest sign of a typical attack for best efficacy; keep a headache diary to identify triggers and measure treatment response objectively; discuss preventive therapy after 3 months if attacks are frequent or disabling. Patient tips.
Representative clinical quote
"Treat the attack early, personalize prevention, and never underestimate structured behavioural care," - Headache guideline panelist, International Headache Society update, April 2025. Guideline quote.
Quick reference checklist for clinicians
- Confirm migraine diagnosis with history and red-flag screen before treatment decisions. Diagnosis check.
- Offer evidence-based acute therapy and limit analgesic days to avoid MOH. Acute protocol.
- For ≥4 attacks/month or substantial disability, discuss preventive options including CGRP-targeted therapy where appropriate. Prevention trigger.
- Incorporate CBT, sleep hygiene, and trigger management alongside medications. Multimodal care.
- Reassess at 8-12 weeks and escalate or refer if inadequate response. Follow-up timing.
Expert answers to Evidence Based Migraine Treatments Worth Trying Now queries
What is the most effective preventive medication?
Answer: CGRP monoclonal antibodies show the highest and most consistent effect size in modern trials for reducing monthly migraine days, particularly in patients with frequent episodic or chronic migraine, but the best preventive for an individual depends on comorbidities, cost, and prior response to treatments. Most effective preventive.
How quickly do preventives work?
Answer: Many preventives demonstrate meaningful benefit by 8-12 weeks; CGRP monoclonal antibodies often show measurable reductions within 4 weeks and are typically evaluated at 12 weeks for decision-making. Onset timing.
Can I prevent migraine without drugs?
Answer: Yes-structured interventions (regular sleep, hydration, aerobic exercise, CBT/biofeedback, trigger avoidance) can reduce frequency and severity and are recommended as adjuncts or first-line for some patients; these methods rarely provide complete remission but improve function. Non-drug prevention.
When should I see a specialist?
Answer: See a headache specialist when attacks are refractory to two or more preventives, when migraine is chronic (≥15 headache days/month), when unusual neurological features occur, or when diagnosis is uncertain. Specialist referral.
Are there new drugs I should know about?
Answer: Since 2018 a new class-CGRP antagonists (both monoclonal antibodies and small-molecule gepants)-and lasmiditan (a 5-HT1F agonist) have expanded options; 2024-2025 guideline updates integrated these into standard care for appropriate patients. New drug classes.